Literature DB >> 8641630

Angiographic-guided embolization of metastatic invasive mole.

M W Method1, M Hirschfield, H E Everette.   

Abstract

BACKGROUND: The friable and hypervascular nature of a metastatic invasive mole places the patient at risk for significant hemorrhage. Bleeding is the chief cause of morbidity and mortality in patients with a histopathological diagnosis of invasive mole. Bleeding from vaginal metastatic lesions can be controlled by packing the vagina and local excision if necessary. Often the results are less than satisfactory. CASE: This case describes a 43-year-old Hispanic female with metastatic invasive mole to the vagina. Following chemotherapy, she underwent life-threatening hemorrhage requiring hospitalization and multiple transfusions. The metastatic lesions were successfully embolized with gelfoam by selective angiography. The patient required minimal additional chemotherapy and is currently without evidence of disease.
CONCLUSIONS: The technique of angiographic embolization is emerging as a successful and minimally invasive procedure as illustrated in this presentation. Prophylactic embolization with or prior to the administration of chemotherapy in the management of metastatic invasive mole is discussed and may play a role in the primary therapy of this condition.

Entities:  

Mesh:

Year:  1996        PMID: 8641630     DOI: 10.1006/gyno.1996.0171

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Transcatheter Artery Embolization for Postoperative Haemorrhage after Arterio-Venous Malformation - Safer Option.

Authors:  Panda Subrat; Sharma Nalini; Khan Dina Aisha; Saha Anusmita; Das Rituparna; Phukan Pranjal
Journal:  Acta Med Litu       Date:  2021-03-09

2.  Methotrexate-induced hemothorax in a woman with low-risk metastatic gestational trophoblastic disease.

Authors:  Yuji Ohki; Hisako Yamada; Yusuke Taira; Wataru Kudaka; Yoichi Aoki
Journal:  Gynecol Oncol Rep       Date:  2019-11-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.